07 March 2025
07 March 2025
Funding for women’s health remains disproportionately low, despite its significant economic potential.
While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.
Scientists have successfully demonstrated the chip mediates drug efficacy tests on cancer models.
The company is planning an NDA submission for the neuroendocrine tumour-targeting ITM-11 later in 2025.
The JV will leverage the dual-arm robot Maholo, developed by Yaskawa subsidiary the Robotic Biology Institute.
The award of ODD status follows the completion of the single-dose Phase I ReSPECT-LM trial.
The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
